Download presentation
Presentation is loading. Please wait.
Published byHerman Tedjo Modified over 6 years ago
1
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia
by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C. Badoux, Steliana Calin, James M. Reuben, Susan O’Brien, Steven M. Kornblau, Hagop M. Kantarjian, Hui Gao, and Alessandra Ferrajoli Blood Volume 122(5): August 1, 2013 ©2013 by American Society of Hematology
2
Changes in T-cell numbers and plasma immunoglobulin levels during therapy with lenalidomide.
Changes in T-cell numbers and plasma immunoglobulin levels during therapy with lenalidomide. (A) Peripheral CD3+ T-cell numbers (mean values ± 1 standard deviation) measured at baseline and during treatment with lenalidomide in 31 LTRs. (B) Percentages of CD4 and CD8+ measured at baseline and during treatment with lenalidomide in 31 LTRs. Baseline median absolute value of CD4 and CD8 was 271 and 176 × 103/mL, respectively, and after 60 months increased to 456 and 362 × 103/mL, respectively. (C) Increase in plasma immunoglobulin measured in 31 LTRs during treatment with lenalidomide when compared with baseline (P < .001) . Values are expressed as percentage change from baseline, mean values ± 1 standard deviation. Median baseline were IgG, 729 ( ) mg/dL; IgA, 91 (15-223) mg/dL; and IgM, 27 (0-485) mg/dL. Baseline IgG, IgA, and IgM levels were less than the normal range in 15 (43%), 14 (40%), and 22 (63%) LTRs, and later normalized in 58%, 57%, and 45% of them, respectively. Paolo Strati et al. Blood 2013;122: ©2013 by American Society of Hematology
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.